The role of thymus and activation-regulated chemokine as a marker of severity of atopic dermatitis - 11/01/21
Doi : 10.1016/j.jaad.2020.05.052
Himadri, MD a, Renu George, MD a, ⁎ 
, Lydia Mathew, MD a, Vanitha Shanmugam, MSc b, Thenmozhi Mani, PhD c, Lakshmanan Jeyaseelan, PhD c
, Lydia Mathew, MD a, Vanitha Shanmugam, MSc b, Thenmozhi Mani, PhD c, Lakshmanan Jeyaseelan, PhD c a Department of Dermatology, Venereology and Leprosy, Christian Medical College, Vellore, Tamil Nadu, India
b Department of Biochemistry, Christian Medical College, Vellore, Tamil Nadu, India
c Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India
∗Correspondence to: Renu George, MD, Department of Dermatology, Venereology, and Leprosy, Unit 1, Christian Medical College, Vellore, Tamil Nadu, India 632004Department of Dermatology, Venereology, and LeprosyUnit 1Christian Medical CollegeVelloreTamil Nadu632004India
| Funding sources: Supported by a fluid research grant, Christian Medical College, Vellore. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Reviewed and approved by IRB (Research and Ethics Committee) (IRB no. 10320). |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 84 - N° 2
P. 545-547 - février 2021 Retour au numéro
Article précédent
- Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: A multicenter, randomized, double-blind, double-dummy, pilot study
- Ben Wang, Xin Yuan, Xin Huang, Yan Tang, Zhixiang Zhao, Bin Yang, Baoqi Yang, Yue Zheng, Chao Yuan, Hongfu Xie, Ji Li
- One-year real-world clinical effectiveness, safety, and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: A single-center retrospective study
- Hideaki Uchida, Masahiro Kamata, Aika Kato, Itsumi Mizukawa, Ayu Watanabe, Ai Agematsu, Mayumi Nagata, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Takamitsu Ohnishi, Yayoi Tada
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?